急性肺损伤／急性呼吸窘迫综合征药物治疗进展  

Progression of pharmacotherapy in acute lung injury/acute respiratory distress syndrome

作　　者：韩力[1] 时国朝[1] 李庆云[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院呼吸科,200025

出　　处：《国际呼吸杂志》2007年第5期333-337,共5页International Journal of Respiration

摘　　要：急性肺损伤／急性呼吸窘迫综合征是全身过度炎症反应在肺部的表现，复杂的发病机制为药物治疗提供了可能的靶点，对此也进行了相当多的探索。部分药物可以改善氧合，减少机械通气时间等，但尚无一种药物被大规模多中心随机对照试验证明可以对所有患者降低死亡率，改善预后。其本身的不均一性可能有影响，对单一环节的干预效果有限。Acute lung injury（ALI）/acute respiratory distress syndrome（ARDS） is the pulmonary manifestation of systemic excessive inflammation. Complicated pathogenesis provided possible target points of pharmacotherapy,and considerable researches have also been conducted in this area. Though some drugs can ameliorate oxygenation and reduce the period of mechanical ventilation, no drugs so far have been proved,under the randomized, controlled trials in large-scaled multi-centres, to be able to effectively lower mortality and improve prognosis over all. The inherent heterogeneity may have an influence on it, also its single step interference may have limited effect.

关 键 词：急性肺损伤 急性呼吸窘迫综合征 药物治疗 

分 类 号：R563[医药卫生—呼吸系统]